Literature DB >> 18311114

Giant cell tumor of bone express p63.

Brendan C Dickson1, Shu-Qiu Li, Jay S Wunder, Peter C Ferguson, Behnam Eslami, Joel A Werier, Robert E Turcotte, Rita A Kandel.   

Abstract

p63 contributes to skeletal development and tumor formation; however, little is known regarding its activity in the context of bone and soft tissue neoplasms. The purpose of this study was to investigate p63 expression in giant cell tumor of bone and to determine whether it can be used to discriminate between other giant cell-rich tumors. Seventeen cases of giant cell tumor of bone were examined to determine the cell type expressing p63 and identify the isoforms present. Total RNA or cell protein was extracted from mononuclear- or giant cell-enriched fractions or intact giant cell tumor of bone and examined by RT-PCR or western blot, respectively. Immunohistochemistry was used to evaluate p63 expression in paraffin embedded sections of giant cell tumor of bone and in tumors containing multinucleated giant cells, including: giant cell tumor of tendon sheath, pigmented villonodular synovitis, aneurysmal bone cyst, chondroblastoma, and central giant cell granuloma. The mononuclear cell component in all cases of giant cell tumor of bone was found to express all forms of TAp63 (alpha, beta, and gamma), whereas only low levels of the TAp63 alpha and beta isoforms were detected in multinucleated cells; DeltaNp63 was not detected in these tumors. Western blot analysis identified p63 protein as being predominately localized to mononuclear cells compared to giant cells. This was confirmed by immunohistochemical staining of paraffin-embedded tumor sections, with expression identified in all cases of giant cell tumor of bone. Only a proportion of cases of aneurysmal bone cyst and chondroblastoma showed p63 immunoreactivity whereas it was not detected in central giant cell granuloma, giant cell tumor of tendon sheath, or pigmented villonodular synovitis. The differential expression of p63 in giant cell tumor of bone and central giant cell granuloma suggest that these two tumors may have a different pathogenesis. Moreover, p63 may be a useful biomarker to differentiate giant cell tumor of bone from central giant cell granuloma and other giant cell-rich tumors, such as giant cell tumor of tendon sheath and pigmented villonodular synovitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18311114     DOI: 10.1038/modpathol.2008.29

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  24 in total

1.  Nuclear p63 expression in osteoblastic tumors.

Authors:  Michael E Kallen; Melinda E Sanders; Adriana L Gonzalez; Jennifer O Black; Vicki L Keedy; Kenneth R Hande; Kelly C Homlar; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Cheryl M Coffin; Justin M M Cates
Journal:  Tumour Biol       Date:  2012-05-25

Review 2.  Prognosis of local recurrence in giant cell tumour of bone: what can we do?

Authors:  Yifeng He; Ji Zhang; Xiaoyi Ding
Journal:  Radiol Med       Date:  2017-03-07       Impact factor: 3.469

3.  Factors influencing multinucleated giant cell formation in vitro.

Authors:  Kevin L Trout; Andrij Holian
Journal:  Immunobiology       Date:  2019-08-10       Impact factor: 3.144

4.  A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases.

Authors:  Ira J Miller; Alan Blank; Suellen M Yin; Allison McNickle; Robert Gray; Steven Gitelis
Journal:  Diagn Pathol       Date:  2010-09-22       Impact factor: 2.644

Review 5.  Giant-cell tumor of bone, anti-RANKL therapy.

Authors:  Armelle Dufresne; Olfa Derbel; Philippe Cassier; Gualter Vaz; Anne-Valérie Decouvelaere; Jean-Yves Blay
Journal:  Bonekey Rep       Date:  2012-09-05

6.  A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained.

Authors:  André Maues De Paula; Alexandre Vasiljevic; Roch Giorgi; Anne Gomez-Brouchet; Sébastien Aubert; Xavier Leroy; Hélène Duval; Gonzague de Pinieux; Corinne Bouvier
Journal:  Virchows Arch       Date:  2014-08-07       Impact factor: 4.064

7.  Smad3 is the key to transforming growth factor-β1-induced osteoclast differentiation in giant cell tumor of bone.

Authors:  Zhiyuan Lou; Yi Yang; Tingting Ren; Shun Tang; Xianbo Peng; Qunshan Lu; Yifeng Sun; Wei Guo
Journal:  Med Oncol       Date:  2013-05-21       Impact factor: 3.064

8.  Giant cell tumour and central giant cell reparative granuloma of the skull: do these represent ends of a spectrum? A case report and literature review.

Authors:  Sonia Saw; Nick Thomas; Michael J Gleeson; István Bódi; Steve Connor; Tibor Hortobágyi
Journal:  Pathol Oncol Res       Date:  2008-11-15       Impact factor: 3.201

9.  Giant-cell tumors of the temporal bone: management strategies.

Authors:  Brandon Isaacson; Wayne Berryhill; H Alexander Arts
Journal:  Skull Base       Date:  2009-07

10.  A case of recurrent multifocal central giant cell granulomas.

Authors:  Elizabeth Bilodeau; Khalid Chowdhury; Bobby Collins
Journal:  Head Neck Pathol       Date:  2009-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.